AGC Biologics, a leading Contract Development and Manufacturing Organization (CDMO) in the biopharmaceutical industry, has announced the appointment of Dr. Christoph Winterhalter as its new Chief Business Officer. With over 30 years of experience in the life science industry, Winterhalter is tasked with overseeing corporate strategy, business development, new business initiatives, and global marketing for AGC Biologics' CDMO network. His extensive background includes developing strategies for sustainable business growth, leading global teams, and establishing strategic partnerships with major pharmaceutical companies.
Before this promotion, Winterhalter served as the Senior Vice President of Business Development for Europe, the Middle East, and Africa (EMEA) at AGC Biologics. His previous role at Rentschler Biopharma as Senior Vice President of Global Business Development saw him triple the company's top-line sales numbers, showcasing his ability to drive significant business growth. AGC Biologics' CEO, Patricio Massera, praised Winterhalter's unique blend of technical expertise and business acumen, emphasizing his potential to contribute to the company's mission of enabling life-changing therapies for patients worldwide.
Winterhalter's appointment is a strategic move for AGC Biologics as it seeks to expand its global footprint and enhance its services in the competitive biopharmaceutical CDMO space. His leadership is expected to foster new partnerships and drive innovation in the development and manufacturing of biopharmaceuticals. Winterhalter expressed his enthusiasm for his new role, highlighting his commitment to working closely with the executive team and partners to bring innovative treatments to market. For more information on AGC Biologics and its services, visit https://www.agcbio.com.
